Addendum
Dapagliflozin (type 1 diabetes mellitus) - Addendum to Commission A19-37
Report documents
-
Addendum
Dapagliflozin (type 1 diabetes mellitus) - Addendum to Commission A19-37
Dossier assessment
Adults with type 1 diabetes and body mass index ≥ 27 kg/m2, when insuline alone provides no adequate glycaemic control despite optimum insulin therapy
Due to data subsequently submitted now indication of minor added benefit for patients in whom the inadequate glycaemic control is not associated with severe hypoglycaemia
Additional information
Federal Joint Committee (G-BA)
2019-10-17 A G-BA decision was published.
Project details
- Project no.
- A19-79
- Commission
- Commission awarded on 09.09.2019 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Dapagliflozin (type 1 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed